From new immunotherapy approaches to insights into environmental risk, research presented at the American Urological Association (AUA) Annual Meeting in Washington, DC, highlights meaningful progress ...

A new survey undertaken by the Harris Poll for Johnson & Johnson has shown how standard forms of surgery and treatment for ...

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® ...

With the help of DNA testing company Natera and its personalized molecular residual disease (MRD) blood test Signatera, Roche ...

An innovative treatment for bladder cancer successfully prevented the recurrence of tumors and improved survival rates following surgery.

Bladder cancer has been billed by AstraZeneca as a key growth area for its immunotherapy Imfinzi, an ambition that has now ...

News, features, and commentary about cancer-related issues ...

The Anglo-Swedish drugmaker, however, said overall survival from a combination of its two cancer drugs Imfinzi and Imjudo ...

High-level results from a planned interim analysis of the VOLGA Phase III trial showed perioperative treatment with Imfinzi (durvalumab) in ...

A Mansfield man's routine health screenings eventually uncovered cancer, but advanced robotic technology at Mount Carmel St.